Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction

• DOI: 10.1038/s41598-021-85949-1
• Publication Date: 2021-03-24T11:04:07Z
• Authors: Cecilia Veraar; Jonathan Kliman; Alberto Benazzo; Felicitas Oberndo...; Maria Laggner; Philipp Hacker; Thomas Raunegger; Stefan Janik; Peter Jaksch; Walter Klepetko; Hendrik J. Ankersmit; Bernhard Moser
• Keywords: Adult; Male; Science; Bronchi; Azithromycin; Article; 03 medical and health sciences; Lipocalin-2; Humans; Transplantation, Homologous; Bronchiolitis Obliterans; Aged; 0303 health sciences; Q; R; Middle Aged; Activins; 3. Good health; Phenotype; Matrix Metalloproteinase 9; Medicine; Cytokines; Female; Primary Graft Dysfunction; Biomarkers; Lung Transplantation

Abstract Chronic Lung Allograft Dysfunction (CLAD), manifesting as Bronchiolitis Obliterans Syndrome (BOS) or Restrictive (RAS), is the main reason for adverse long-term outcome after Transplantation (LTX). Until now, no specific biomarkers exist to differentiate between CLAD phenotypes. Therefore, we sought find suitable cytokines distinguish BOS, RAS and Azithromycin Responsive (ARAD); reveal potential similarities differences end-stage fibrotic diseases. We observed significantly increased Lipocalin-2 serum concentrations in compared BOS patients. In addition, patients immunohistochemistry revealed expression bronchial epithelium alveolar walls. Patients with ARAD showed lower Activin-A Stable-LTX Further, of were predictors worse freedom-from-CLAD These serve promising prediction seem implementation clinical practice.